financetom
Business
financetom
/
Business
/
Caleres Reports Lower Q4 Sales, Cautious Outlook For 2025 Amid Inflation And Tariffs
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Caleres Reports Lower Q4 Sales, Cautious Outlook For 2025 Amid Inflation And Tariffs
Mar 20, 2025 9:06 AM

Caleres, Inc. ( CAL ) shares are trading higher after the company reported fourth-quarter results.

Revenues fell 8.3% year over year to $639.2 million, missing the analyst consensus of $653.86 million.

Famous Footwear sales fell 9.6% Y/Y, with comparable store sales down 2.9%. Brand Portfolio sales decreased 7.2% in the quarter.

“Famous Footwear’s business softened in the quarter, but we maximized key selling periods. We invested to support our long-term growth while continuing to evolve our supply chain and further mitigate the impact of additional tariffs,” said Jay Schmidt, president and chief executive officer.

The company’s gross margin rate contracted 80 basis points year over year to 43.0% and adjusted EBITDA fell to $29.0 million.

Adjusted EPS of 33 cents beat the consensus of 24 cents.

In 2024, Caleres ( CAL ) returned $74.7 million in cash to shareholders through dividends and share repurchases. Borrowings under the revolving credit facility totaled $219.5 million at the end of the period.

“As we look forward to 2025 and the macroeconomic environment with persistent inflation and newer tariffs, we believe it is prudent to take a conservative view for the year,” added Schmidt.

Outlook: The company expects FY25 net sales to decline by 1% to up 1% and EPS of $2.80 – $3.20 (consensus $3.21).

For the first quarter, Caleres ( CAL ) expects sales to decline 5% – 6% and EPS of $0.35 – $0.40 vs. consensus of $0.87.

Caleres ( CAL ) said it currently expects 75% of its Brand Portfolio, and an even greater percentage of Lead Brands’ sourcing to be outside of China by the second half of 2025.

Last month, the company inked a deal to acquire Stuart Weitzman from Tapestry for $105 million. The guidance excludes this acquisition, which is expected to close in the summer of 2025.

Price Action: CAL shares are down 2.46% at $15.99 at the last check Thursday.

Read Next:

Temu Parent PDD Holdings Drops After Q4 Revenue Miss: Details

Image via Shutterstock.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Expeditors International of Washington's Earnings to Benefit From Sharp Rise in Ocean Rates, UBS Says
Expeditors International of Washington's Earnings to Benefit From Sharp Rise in Ocean Rates, UBS Says
Aug 1, 2024
01:04 PM EDT, 08/01/2024 (MT Newswires) -- Expeditors International of Washington's ( EXPD ) earnings are due to benefit from a sharp rise in ocean container shipping rates, UBS said in a note emailed Thursday. Oceanfreight contributed 25% towards the company's gross revenue in 2023 and is expected to account for 33% of revenue in 2024 as shipping rates soared...
Update: Moderna Shares Dropped After Q2 Results
Update: Moderna Shares Dropped After Q2 Results
Aug 1, 2024
01:02 PM EDT, 08/01/2024 (MT Newswires) -- (Updates to add stock move in the headline and the first paragraph.) Moderna ( MRNA ) shares dropped nearly 21% in recent Thursday trading after the company reported its results for Q2. The company reported a Q2 loss Thursday of $3.33 per diluted share, narrowing from a loss of $3.62 a year earlier....
Lilly CEO says weight-loss drug shortage to end 'very soon', Bloomberg News reports
Lilly CEO says weight-loss drug shortage to end 'very soon', Bloomberg News reports
Aug 1, 2024
Aug 1 (Reuters) - U.S. drugmaker Eli Lilly ( LLY ) expects its blockbuster weight-loss drug to officially come out of shortage in the United States in coming days, Bloomberg News reported on Thursday, citing an interview with the company's chief executive officer, David Ricks. Lilly's drug, tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight management, will cease...
Update: Air Products and Chemicals' Fiscal Q3 Adjusted EPS Rises, Revenue Falls; Provides Q4 Guidance; Shares Up 10%
Update: Air Products and Chemicals' Fiscal Q3 Adjusted EPS Rises, Revenue Falls; Provides Q4 Guidance; Shares Up 10%
Aug 1, 2024
01:03 PM EDT, 08/01/2024 (MT Newswires) -- (Updates with stock movement in last paragraph.) Air Products and Chemicals ( APD ) reported Fiscal Q3 adjusted earnings of $3.20 per diluted share on Thursday, up from $2.98 a year earlier. Analysts polled by Capital IQ expected $3.04 per share. Revenue for the quarter ended June 30 was $2.99 billion compared with...
Copyright 2023-2026 - www.financetom.com All Rights Reserved